Scarica l'app Stockscreener
9.76
1.67%
0.16
Pre-mercato:
9.96
0.20
+2.05%
Precedente Chiudi:
$9.60
Aprire:
$9.775
Volume 24 ore:
1.22M
Relative Volume:
0.95
Capitalizzazione di mercato:
$452.32M
Reddito:
$217.11M
Utile/perdita netta:
$-651.19M
Rapporto P/E:
-0.7513
EPS:
-12.99
Flusso di cassa netto:
$-387.26M
1 W Prestazione:
-9.55%
1M Prestazione:
+14.15%
6M Prestazione:
-9.88%
1 anno Prestazione:
-26.57%
Intervallo 1D:
$9.5735
$10.15
Intervallo di 1 settimana:
$9.27
$10.50
Portata 52W:
$5.00
$16.85
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Nome
Ginkgo Bioworks Holdings Inc
Settore
Industria
Telefono
(877) 442-5362
Indirizzo
27 DRYDOCK AVENUE, BOSTON
Confronta DNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNA
Ginkgo Bioworks Holdings Inc
|
9.76 | 631.56M | 217.11M | -651.19M | -387.26M | -12.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-15 | Downgrade | BTIG Research | Neutral → Sell |
| 2024-05-10 | Downgrade | William Blair | Mkt Perform → Underperform |
| 2023-11-14 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-11-09 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-06-02 | Downgrade | Goldman | Neutral → Sell |
| 2023-05-11 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2022-11-29 | Iniziato | Berenberg | Buy |
| 2022-10-04 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-02 | Ripresa | Cowen | Outperform |
| 2022-02-23 | Iniziato | Goldman | Neutral |
| 2022-02-01 | Iniziato | BofA Securities | Neutral |
| 2022-01-28 | Iniziato | BofA Securities | Buy |
| 2022-01-07 | Iniziato | BTIG Research | Buy |
| 2021-11-29 | Iniziato | Jefferies | Buy |
| 2021-10-13 | Iniziato | Raymond James | Outperform |
| 2021-10-12 | Iniziato | William Blair | Outperform |
| 2021-09-20 | Iniziato | HSBC Securities | Buy |
Mostra tutto
Ginkgo Bioworks Holdings Inc Borsa (DNA) Ultime notizie
What drives Ginkgo Bioworks Holdings Inc. stock priceConsistent high-yield stocks - Jammu Links News
Ginkgo Bioworks launches cost-effective ADME profiling service By Investing.com - Investing.com Canada
Ginkgo Bioworks Launches ADME Profiling Service Using Lab Automation, Offering a US-based Operation That Will Match or Beat Pricing Quotes from Chinese or Other International Vendors - MarketScreener
Ginkgo Disrupts Drug Discovery Market with US-Based ADME Service Matching Chinese Prices - Stock Titan
Ginkgo Bioworks Holdings, Inc. (DNA) Outperforms Broader Market: What You Need to Know - MSN
Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Not Quite Adding Up - 富途牛牛
When the Price of (DNA) Talks, People Listen - news.stocktradersdaily.com
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Sinks As Market Gains: Here's Why - sharewise.com
Ginkgo Bioworks (DNA) Shares Soar 5.29% on Q2 Earnings - AInvest
Ginkgo Bioworks (DNA) Soars 18.9%: Is Further Upside Left in the Stock? - MSN
(DNA) On The My Stocks Page - news.stocktradersdaily.com
Ginkgo Bioworks Holdings, Inc.(NYSE: DNA) added to Russell Small Cap Comp Value Index - MarketScreener
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Moves 1.41%: What You Should Know - MSN
Is Ginkgo Bioworks Holdings, Inc. overvalued or undervalued? - MarketsMojo
Lobbying Update: $10,000 of GINKGO BIOWORKS lobbying was just disclosed - Nasdaq
Ginkgo Bioworks Holds Annual Shareholder Meeting, Elects Directors - TipRanks
5 "Best" Publicly Traded Synthetic Biology Companies - Securities.io
Ginkgo Bioworks (DNA) Sees 5.4% Increase in Stock Price | DNA Stock News - GuruFocus
Where are the Opportunities in (DNA) - news.stocktradersdaily.com
Ginkgo Bioworks: Hedge Funds Pull Back and Other Important Updates - TradingView
Squarepoint Ops LLC Has $417,000 Stock Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - Defense World
From Promise to Peril: The Downfall of Ginkgo Bioworks - TradingView
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Slides as Market Rises: Facts to Know Before You Trade - MSN
Top 5 CRISPR Companies To Invest In (June 2025) - Securities.io
Northern Trust Corp Buys 9,791 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - Defense World
Analysts Offer Insights on Healthcare Companies: Ginkgo Bioworks Holdings (DNA) and Elanco Animal Health (ELAN) - The Globe and Mail
(DNA) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Millennium Management LLC Has $6.58 Million Stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - Defense World
Ginkgo Bioworks Partners with HaDEA in Up to €24 Million Consortium Project to Deliver Next-Generation 'Agnostic Diagnostics' for Respiratory Viruses at the Point of Care - Quantisnow
Ginkgo Bioworks: Cost-Cutting Efforts Aren't Enough (NYSE:DNA) - Seeking Alpha
Major Moves And Shakes In Health Care Sector - Finimize
Sector Update: Health Care - marketscreener.com
Ginkgo Bioworks announces CFO transition - MSN
Ginkgo Bioworks (DNA) Announces CFO Transition - GuruFocus
Ginkgo Bioworks CFO Mark Dmytruk to Resign, Steven Coen Appointed as New Finance Chief - marketscreener.com
Ginkgo Bioworks Announces Appointment Of Steven Coen As Chief Financial Officer - marketscreener.com
Charles River Laboratories (CRL): Leadership Change at Ginkgo Bi - GuruFocus
Charles River Laboratories (CRL): Leadership Change at Ginkgo Bioworks | CRL Stock News - GuruFocus
Ginkgo Bioworks Announces Appointment of Steven Coen as Chief Financial Officer - StreetInsider
Ginkgo Bioworks Promotes 30-Year Finance Expert to CFO Role, Maintains 2026 EBITDA Target - Stock Titan
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) is a favorite amongst institutional investors who own 56% - Yahoo Finance
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Moves -1.94%: What You Should Know - MSN
Twist Bioscience and Ginkgo Bioworks update 2022 partnership - MSN
Ginkgo outlines $250M cost reduction target and tools expansion in Q1 2025 update - MSN
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year - simplywall.st
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Acquired by Barclays PLC - Defense World
Ginkgo Bioworks Holdings, Inc. (DNA): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside Potential - MSN
Billionaire Nicholas J. Pritzker’s 8 Stocks with Huge Upside Potential - Insider Monkey
GINKGO BIOWORKS HOLDINGS, INC. F/K/A SOARING EAGLE ACQUISITION CORP. (NYSE: DNA, SRNG) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Cla - ACCESS Newswire
Twist Bioscience and Ginkgo Bioworks Revise Collaboration - Stock Titan
GINKGO BIOWORKS HOLDINGS, INC. F/K/A SOARING EAGLE ACQUISITION CORP. (NYSE:DNA, SRNG) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Cla - ACCESS Newswire
Ginkgo Bioworks Holdings Inc Azioni (DNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.64%
0.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):